Filing summary
Entity and period: The supplied filing is Spherix Incorporated’s Form 10-K for the fiscal year ended December 31, 2015, not a filing under the requested company name, Dominari Holdings Inc. Verify the issuer and filing period before relying on this summary. Financial statement amounts below are in U.S. dollars; figures described as millions are rounded.
Business context
Spherix had shifted from drug development to acquiring and monetizing intellectual property. Its portfolio comprised more than 290 patents and applications, principally in wireless communications and telecommunications. The business relied on licensing and patent enforcement, had limited operating history in this model, and generated only nominal revenue.
Financial performance and liquidity
| Metric | 2015 | 2014 |
|---|---|---|
| Revenue | $33,000 | $10,000 |
| Operating loss | $52.0 million | $30.6 million |
| Net loss | $51.5 million | $30.5 million |
| Net loss attributable to common stockholders | $42.3 million | $30.5 million |
| Net cash used in operating activities | $4.6 million | $9.5 million |
| Net cash provided by financing activities | $3.8 million | $8.2 million |
- Gross margin is not meaningfully assessable from the filing’s presentation: revenue was nominal and the company reported substantial operating losses.
- At year-end, cash and cash equivalents were $142,000 and marketable securities were $3.392 million. Current assets were $3.864 million versus current liabilities of $4.456 million, a working-capital deficit of about $592,000.
- Total assets were $13.694 million, down from $61.158 million in 2014; stockholders’ equity was $8.750 million, versus $53.586 million. Patent portfolios, net, fell to $9.799 million from $55.004 million, and goodwill was reduced to zero.
- The balance sheet lists no conventional borrowings. It includes $2.959 million of warrant liabilities, deferred revenue and lease liabilities; total liabilities were $4.944 million. The filing states that liquidity was insufficient to fund operations and other requirements for the foreseeable future.
Changes, unusual items and transactions
- Operating loss increased 70% year over year. The principal driver was a $40.6 million impairment charge in 2015: $38.9 million against patent assets and $1.7 million against goodwill. No comparable impairment was recorded in 2014.
- Lower stock-based compensation and professional expenses partly offset the impairment. Stock-based compensation fell to $371,000 from $12.676 million, and professional fees declined to $2.780 million from $4.520 million.
- The November 2015 RPX license agreement provided $300,000 cash, cancellation of remaining Series I preferred stock and its $5 million scheduled redemption obligation, cancellation of 57,076 Series H preferred shares, and release of a security interest on 101 patents. The extinguishment generated a $9.485 million deemed capital contribution. The agreement licensed RPX members and settled the company’s Cisco and Juniper disputes; it also imposed certain future licensing obligations.
- A Huawei settlement generated a one-time $295,000 payment. Other income also included marketable-securities results and a non-cash warrant fair-value gain.
- 2015 financing included net proceeds of approximately $1.3 million from a July stock-and-warrant offering and $3.4 million from a December offering. The company reported a $323,000 deemed dividend from the Series K preferred stock’s beneficial conversion feature.
Outlook, risks and contingencies
- The auditor reported substantial doubt about the company’s ability to continue as a going concern, citing recurring losses and the need to raise additional funds. Management said it intended to pursue financing and monetize its patent portfolio; availability and terms of financing were uncertain.
- Management and the board were reviewing strategic alternatives, including a sale, merger, asset disposition, partnership, acquisition or continued operation under the existing plan. No outcome was assured.
- Patent enforcement was a central business risk: litigation could be lengthy and costly, patents could be challenged or invalidated, and recoveries could be delayed or inadequate. Rockstar participation payments could consume a substantial portion of future recoveries.
- In February 2016, after year-end, the PTAB found eight of 15 asserted claims of one patent and all asserted claims of another patent invalid in the VTech and Uniden proceedings. The cases remained stayed, with appeal and resolution steps pending as of the filing.
- Internal control over financial reporting and disclosure controls were deemed ineffective at December 31, 2015 because of inadequate segregation of duties and insufficient controls to capture material transactions and developments.
- After year-end, the company effected a 1-for-19 reverse stock split and reported regaining Nasdaq’s minimum-bid-price compliance on March 18, 2016. The filing cautions that continued compliance and stock liquidity were not assured.
Most important facts to verify
- Confirm that Spherix Incorporated and fiscal 2015 are the intended issuer and period; they do not match the request metadata.
- Review the going-concern disclosure, available cash and securities, working-capital deficit, and subsequent financing or capital needs.
- Assess the assumptions behind the patent and goodwill impairments and the remaining carrying value and useful life of the patent portfolio.
- Check current status and appeal outcomes for the VTech and Uniden proceedings, and the scope and economics of the RPX and Huawei agreements.
- Confirm the potential dilution and settlement exposure from outstanding warrants and convertible preferred stock; the filing reports 3.125 million potentially dilutive shares, excluded from diluted loss per share as antidilutive.
- Verify remediation of the disclosed material weaknesses and the company’s Nasdaq listing status after the reported reverse split.